Journal ArticleDOI
Targeting public neoantigens for cancer immunotherapy.
Alexander H. Pearlman,Alexander H. Pearlman,Michael S. Hwang,Maximilian F. Konig,Emily Han-Chung Hsiue,Emily Han-Chung Hsiue,Jacqueline Douglass,Jacqueline Douglass,Sarah R. DiNapoli,Sarah R. DiNapoli,Brian J. Mog,Chetan Bettegowda,Drew M. Pardoll,Sandra B. Gabelli,Nicholas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Shibin Zhou +17 more
- Vol. 2, Iss: 5, pp 487-497
Reads0
Chats0
TLDR
The opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them are reviewed.Abstract:
Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them. Zhou and colleagues discuss the opportunities and challenges in targeting public neoantigens for cancer immunotherapy.read more
Citations
More filters
Journal ArticleDOI
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich,Quinlen F. Marshall,John M. Warrington,Rasika Premaratne,Alvin Farrel,David Groff,Wei Li,Moreno Di Marco,Erin Runbeck,Hau Truong,Jugmohit S. Toor,Sarvind Tripathi,Son Nguyen,Helena Shen,Tiffany Noel,Nicole L. Church,Amber K. Weiner,Nathan M. Kendsersky,Daniel Martinez,Rebecca Weisberg,Molly Christie,Laurence C. Eisenlohr,Kristopher R. Bosse,Kristopher R. Bosse,Dimiter S. Dimitrov,Stefan Stevanovic,Nikolaos G. Sgourakis,Ben R. Kiefel,John M. Maris,John M. Maris +29 more
TL;DR: In this article, a peptide-centric chimeric antigen receptor (CAR) was proposed to target unmutated peptide QYNPIRTTF, discovered on HLA-A*24:02, derived from the neuroblastoma dependency gene and master transcriptional regulator PHOX2B.
Journal ArticleDOI
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
TL;DR: The differing mechanisms of T cell antigen recognition and signal transduction mediated through CARs and TCRs are described and both classical and emerging pre-clinical strategies for antigen-specific TCR discovery, enhancement, and validation are discussed.
Journal ArticleDOI
Neoantigens: promising targets for cancer therapy
TL;DR: Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames as mentioned in this paper .
Journal ArticleDOI
Thermal immuno-nanomedicine in cancer
Zhe Yang,Di Gao,Jing Zhao,Gaojie Yang,Mingli Guo,Yiming Wang,Xuechun Ren,Jong Seung Kim,L. Jin,Zhongmin Tian,Jing Zhang +10 more
Journal ArticleDOI
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
TL;DR: In this review, Bewersdorf and Abdel-Wahab discuss the development of promising new molecular targeted approaches for AML, including menin inhibition, novel IDH1/2 inhibitors, and preclinical means to target TET2, ASXL1, and RNA splicing factor mutations.
References
More filters
Journal ArticleDOI
T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexes.
Amalie Kai Bentzen,Lina Such,Kamilla Kjærgaard Jensen,Andrea Marion Marquard,Leon Eyrich Jessen,Natalie J. Miller,Candice D. Church,Rikke Birgitte Lyngaa,David M. Koelle,Jürgen C. Becker,Carsten Linnemann,Ton N. Schumacher,Paolo Marcatili,Paul Nghiem,Morten Nielsen,Sine Reker Hadrup +15 more
TL;DR: The TCR fingerprints of 16 different TCRs were identified and used to predict and validate cross-recognized peptides from the human proteome, demonstrating the value of this strategy for understanding T-cell interactions and assessing potential cross- Recognition before selection of T CRs for clinical development.
Journal ArticleDOI
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Shelly Kalaora,Yochai Wolf,Tali Feferman,Eilon Barnea,Erez Greenstein,Dan Reshef,Itay Tirosh,Alexandre Reuben,Sushant Patkar,Ronen Levy,Juliane Quinkhardt,Tana Omokoko,Nouar Qutob,Ofra Golani,Jianhua Zhang,Xizeng Mao,Xingzhi Song,Chantale Bernatchez,Cara Haymaker,Marie Andrée Forget,Caitlin Creasy,Polina Greenberg,Brett W. Carter,Zachary A. Cooper,Steven A. Rosenberg,Michal Lotem,Ugur Sahin,Guy Shakhar,Eytan Ruppin,Jennifer A. Wargo,Nir Friedman,Arie Admon,Yardena Samuels +32 more
TL;DR: It is shown that a limited set of neoantigen-specific T cells mediates tumor rejection, suggesting that identifying just a few antigens and their corresponding T-cell clones could guide personalized immunotherapy.
Journal ArticleDOI
Degenerate T-cell recognition of peptides on MHC molecules creates large holes in the T-cell repertoire.
TL;DR: Comparing the presented human and bacterial or viral peptides on a large number of MHC molecules suggests that T-cells are expected to remain tolerant for a large fraction of the presented nonself peptides, which provides an explanation for the “holes in the T-cell repertoire”.
Journal ArticleDOI
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.
Christopher L. Nobles,Scott Sherrill-Mix,John K. Everett,Shantan Reddy,Joseph A. Fraietta,David L. Porter,Noelle V. Frey,Saar Gill,Stephan A. Grupp,Shannon L. Maude,Don L. Siegel,Bruce L. Levine,Carl H. June,Simon F. Lacey,J. Joseph Melenhorst,Frederic D. Bushman +15 more
TL;DR: It is found that data from preinfusion products forecasted response in CLL successfully in discovery and validation cohorts and, in day 28 samples, reported responders to CLL therapy with high accuracy.
Journal ArticleDOI
Mutation-Derived Neoantigens for Cancer Immunotherapy.
TL;DR: The spectrum of mutations in multiple indications is reviewed, variations in indication sub-types are shown, and the intra- and inter-indication prevalence of re-occurring mutation neoantigens that could be used for warehouse vaccines and ACT are examined.